vTv Therapeutics (VTVT) Cash & Equivalents (2016 - 2025)
vTv Therapeutics (VTVT) has disclosed Cash & Equivalents for 12 consecutive years, with $88.9 million as the latest value for Q4 2025.
- Quarterly Cash & Equivalents rose 142.02% to $88.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $88.9 million through Dec 2025, up 142.02% year-over-year, with the annual reading at $88.9 million for FY2025, 142.02% up from the prior year.
- Cash & Equivalents hit $88.9 million in Q4 2025 for vTv Therapeutics, down from $98.5 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $98.5 million in Q3 2025 to a low of $8.2 million in Q3 2023.
- Historically, Cash & Equivalents has averaged $29.0 million across 5 years, with a median of $18.3 million in 2022.
- Biggest five-year swings in Cash & Equivalents: soared 1981.03% in 2021 and later plummeted 46.41% in 2023.
- Year by year, Cash & Equivalents stood at $13.4 million in 2021, then dropped by 9.61% to $12.1 million in 2022, then decreased by 22.1% to $9.4 million in 2023, then soared by 289.01% to $36.7 million in 2024, then soared by 142.02% to $88.9 million in 2025.
- Business Quant data shows Cash & Equivalents for VTVT at $88.9 million in Q4 2025, $98.5 million in Q3 2025, and $25.9 million in Q2 2025.